Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Arbele Starts Australian Trial of CDH17xCD3 Bispecific for GI Cancers

publication date: Aug 10, 2022

Arbele, a US-China company developing immunotherapies for gastrointestinal cancers, dosed the first patient in an Australian Phase I trial of ARB202 for patients with advanced gastrointestinal cancers. Arbele claims to be the first company to test the potential of a CDH17xCD3 bispecific T-Cell engager antibody in cancer immunotherapy. Using Abele's patented CDH17 biomarker, the binding affinities of ARB202 toward CDH17 and CD3 allow it to have high specificity and cytotoxicity, while avoiding off-target overactivation of T cells. Arbele is headquartered in Seattle with R&D operations in Hong Kong, Seattle, Sydney, Guangzhou and Singapore. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital